{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:24:19Z","timestamp":1785781459579,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Taibah University Medical Sciences"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jtumed.2025.07.008","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T16:09:51Z","timestamp":1754582991000},"page":"525-532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes of empagliflozin in nondiabetic fatty liver patients: A randomized controlled trial"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3141-3719","authenticated-orcid":false,"given":"Bahaa Osman","family":"Taha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A.","family":"Kobeisy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essam","family":"Abdelmohsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Abdelrhman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa M.","family":"Abokresha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab M.","family":"Hassanein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad H.M.","family":"AbdEllah-Alawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtumed.2025.07.008_bib1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jtumed.2025.07.008_bib2","series-title":"Steatotic liver disease: metabolic dysfunction, alcohol, or both?","author":"Jornayvaz","year":"2023"},{"key":"10.1016\/j.jtumed.2025.07.008_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155246","article-title":"Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD)","volume":"134","author":"Valenzuela-Vallejo","year":"2022","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.jtumed.2025.07.008_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41575-020-0316-6","article-title":"From NAFLD to MAFLD: when pathophysiology succeeds","volume":"17","author":"Tilg","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jtumed.2025.07.008_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J Obes Metab Syndr"},{"issue":"6","key":"10.1016\/j.jtumed.2025.07.008_bib6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jtumed.2025.07.008_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1291501","article-title":"Metabolic-associated fatty liver disease: aselective review of pathogenesis, diagnostic approaches, and therapeutic strategies","volume":"11","author":"Habibullah","year":"2024","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.jtumed.2025.07.008_bib8","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease HHS public access","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jtumed.2025.07.008_bib9","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtumed.2025.07.008_bib10","article-title":"Efficacy of sodium-glucose co-transporter 2 inhibitors in treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"33","author":"Ahmed","year":"2022","journal-title":"Obes Med"},{"key":"10.1016\/j.jtumed.2025.07.008_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174272","article-title":"Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease","volume":"907","author":"Makri","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jtumed.2025.07.008_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.609135","article-title":"Sodium-glucose Co-Transporter 2 inhibitors for non-alcoholic fatty liver disease in Asian patients with type 2 diabetes: a meta-analysis","volume":"11","author":"Wong","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.jtumed.2025.07.008_bib13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s12872-021-02163-7","article-title":"Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure","volume":"21","author":"Nakagaito","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"10.1016\/j.jtumed.2025.07.008_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3164\/jcbn.20-129","article-title":"Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study","volume":"68","author":"Tobita","year":"2021","journal-title":"J Clin Biochem Nutr"},{"issue":"11","key":"10.1016\/j.jtumed.2025.07.008_bib15","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.jtumed.2025.07.008_bib16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/13814780600881268","article-title":"WHO diagnostic criteria as a validation tool for the diagnosis of diabetes mellitus: a study in five European countries","volume":"12","author":"Deckers","year":"2006","journal-title":"Eur J Gen Pract"},{"key":"10.1016\/j.jtumed.2025.07.008_bib17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/RMHP.S285880","article-title":"MAFLD criteria guide the subtyping of patients with fatty liver disease","volume":"14","author":"Huang","year":"2021","journal-title":"Risk Manag Healthc Policy"},{"issue":"4","key":"10.1016\/j.jtumed.2025.07.008_bib18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ajg.2023.08.003","article-title":"Performance of FibroScan in grading steatosis and fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"24","author":"Xu","year":"2023","journal-title":"Arab J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jtumed.2025.07.008_bib19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/gut.2005.069153","article-title":"Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study","volume":"55","author":"Foucher","year":"2006","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.jtumed.2025.07.008_bib20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review","volume":"163","author":"Long","year":"2022","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.jtumed.2025.07.008_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108558","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: an updated meta-analysis of randomized controlled trials","volume":"37","author":"Jin","year":"2023","journal-title":"J Diabetes Complications"},{"issue":"50","key":"10.1016\/j.jtumed.2025.07.008_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013636","article-title":"Optimal cutoff value for assessing changes in intrahepatic fat amount by using the controlled attenuation parameter in a longitudinal setting","volume":"97","author":"Ahn","year":"2018","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.jtumed.2025.07.008_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100765","article-title":"NAFLD VS MAFLD. The evidence-based debate has come. Time to change?","volume":"27","author":"Garc\u00eda-Compe\u00e1n","year":"2022","journal-title":"Ann Hepatol"},{"issue":"8","key":"10.1016\/j.jtumed.2025.07.008_bib24","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jtumed.2025.07.008_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.hnm.2023.200210","article-title":"Visceral fat: a key mediator of NAFLD development and progression","volume":"33","author":"Bansal","year":"2023","journal-title":"Hum Nutr Metab"},{"issue":"9","key":"10.1016\/j.jtumed.2025.07.008_bib26","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","article-title":"Mechanism of increased LDL (Low-density lipoprotein) and decreased triglycerides with SGLT2 (Sodium-Glucose cotransporter 2) inhibition","volume":"38","author":"Basu","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtumed.2025.07.008_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.amsu.2022.103633","article-title":"Effects of novel glucose-lowering drugs on the lipid parameters: a systematic review and meta-analysis","volume":"77","author":"Dar","year":"2022","journal-title":"Ann Med Surg"},{"issue":"17","key":"10.1016\/j.jtumed.2025.07.008_bib28","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1080\/14656566.2020.1795132","article-title":"Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile","volume":"21","author":"Muzurovi\u0107","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jtumed.2025.07.008_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117236","article-title":"SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type","volume":"394","author":"Bechmann","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jtumed.2025.07.008_bib30","article-title":"HbA1C as a biomarker of non-alcoholic fatty liver disease: Comparison with anthropometric parameters","volume":"000","author":"Masroor","year":"2020","journal-title":"J Clin Transl Hepatol"}],"container-title":["Journal of Taibah University Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658361225000770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658361225000770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T15:18:56Z","timestamp":1757085536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1658361225000770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1658361225000770"],"URL":"https:\/\/doi.org\/10.1016\/j.jtumed.2025.07.008","relation":{},"ISSN":["1658-3612"],"issn-type":[{"value":"1658-3612","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of empagliflozin in nondiabetic fatty liver patients: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Taibah University Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtumed.2025.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}